NASDAQ:KNTE

Kinnate Biopharma Competitors

$31.55
+0.17 (+0.54 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$29.79
Now: $31.55
$31.87
50-Day Range
$26.99
MA: $32.59
$37.00
52-Week Range
$24.14
Now: $31.55
$48.75
Volume51,103 shs
Average Volume206,788 shs
Market Capitalization$1.37 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Kinnate Biopharma (NASDAQ:KNTE) Vs. ABCM, SEER, NUVB, IBRX, BCAB, and IMCR

Should you be buying KNTE stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Kinnate Biopharma, including Abcam (ABCM), Seer (SEER), Nuvation Bio (NUVB), ImmunityBio (IBRX), BioAtla (BCAB), and Immunocore (IMCR).

Abcam (NASDAQ:ABCM) and Kinnate Biopharma (NASDAQ:KNTE) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings for Abcam and Kinnate Biopharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Abcam04302.43
Kinnate Biopharma00403.00

Abcam presently has a consensus price target of $22.00, suggesting a potential upside of 10.61%. Kinnate Biopharma has a consensus price target of $52.00, suggesting a potential upside of 64.82%. Given Kinnate Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Kinnate Biopharma is more favorable than Abcam.

Profitability

This table compares Abcam and Kinnate Biopharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AbcamN/AN/AN/A
Kinnate BiopharmaN/AN/AN/A

Earnings and Valuation

This table compares Abcam and Kinnate Biopharma's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AbcamN/AN/AN/AN/AN/A
Kinnate BiopharmaN/AN/AN/AN/AN/A

Summary

Kinnate Biopharma beats Abcam on 3 of the 3 factors compared between the two stocks.

Seer (NASDAQ:SEER) and Kinnate Biopharma (NASDAQ:KNTE) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings for Seer and Kinnate Biopharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Seer02202.50
Kinnate Biopharma00403.00

Seer presently has a consensus price target of $68.00, suggesting a potential upside of 30.79%. Kinnate Biopharma has a consensus price target of $52.00, suggesting a potential upside of 64.82%. Given Kinnate Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Kinnate Biopharma is more favorable than Seer.

Profitability

This table compares Seer and Kinnate Biopharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SeerN/AN/AN/A
Kinnate BiopharmaN/AN/AN/A

Earnings and Valuation

This table compares Seer and Kinnate Biopharma's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SeerN/AN/AN/AN/AN/A
Kinnate BiopharmaN/AN/AN/AN/AN/A

Summary

Kinnate Biopharma beats Seer on 3 of the 3 factors compared between the two stocks.

Nuvation Bio (NYSE:NUVB) and Kinnate Biopharma (NASDAQ:KNTE) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends and analyst recommendations.

Profitability

This table compares Nuvation Bio and Kinnate Biopharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Nuvation BioN/AN/AN/A
Kinnate BiopharmaN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings for Nuvation Bio and Kinnate Biopharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nuvation Bio00603.00
Kinnate Biopharma00403.00

Nuvation Bio presently has a consensus price target of $17.40, suggesting a potential upside of 74.00%. Kinnate Biopharma has a consensus price target of $52.00, suggesting a potential upside of 64.82%. Given Nuvation Bio's higher probable upside, equities analysts plainly believe Nuvation Bio is more favorable than Kinnate Biopharma.

Earnings and Valuation

This table compares Nuvation Bio and Kinnate Biopharma's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nuvation BioN/AN/AN/AN/AN/A
Kinnate BiopharmaN/AN/AN/AN/AN/A

Summary

Nuvation Bio beats Kinnate Biopharma on 2 of the 2 factors compared between the two stocks.

ImmunityBio (NASDAQ:IBRX) and Kinnate Biopharma (NASDAQ:KNTE) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership and analyst recommendations.

Profitability

This table compares ImmunityBio and Kinnate Biopharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ImmunityBioN/AN/AN/A
Kinnate BiopharmaN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for ImmunityBio and Kinnate Biopharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ImmunityBio00103.00
Kinnate Biopharma00403.00

ImmunityBio presently has a consensus price target of $25.00, suggesting a potential upside of 48.19%. Kinnate Biopharma has a consensus price target of $52.00, suggesting a potential upside of 64.82%. Given Kinnate Biopharma's higher probable upside, analysts plainly believe Kinnate Biopharma is more favorable than ImmunityBio.

Earnings & Valuation

This table compares ImmunityBio and Kinnate Biopharma's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunityBioN/AN/AN/AN/AN/A
Kinnate BiopharmaN/AN/AN/AN/AN/A

Summary

Kinnate Biopharma beats ImmunityBio on 2 of the 2 factors compared between the two stocks.

BioAtla (NASDAQ:BCAB) and Kinnate Biopharma (NASDAQ:KNTE) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership and analyst recommendations.

Profitability

This table compares BioAtla and Kinnate Biopharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioAtlaN/AN/AN/A
Kinnate BiopharmaN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for BioAtla and Kinnate Biopharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioAtla00403.00
Kinnate Biopharma00403.00

BioAtla presently has a consensus price target of $58.00, suggesting a potential upside of 22.49%. Kinnate Biopharma has a consensus price target of $52.00, suggesting a potential upside of 64.82%. Given Kinnate Biopharma's higher probable upside, analysts plainly believe Kinnate Biopharma is more favorable than BioAtla.

Earnings & Valuation

This table compares BioAtla and Kinnate Biopharma's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioAtlaN/AN/AN/AN/AN/A
Kinnate BiopharmaN/AN/AN/AN/AN/A

Summary

Kinnate Biopharma beats BioAtla on 1 of the 1 factors compared between the two stocks.

Immunocore (NASDAQ:IMCR) and Kinnate Biopharma (NASDAQ:KNTE) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership and analyst recommendations.

Profitability

This table compares Immunocore and Kinnate Biopharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ImmunocoreN/AN/AN/A
Kinnate BiopharmaN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Immunocore and Kinnate Biopharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Immunocore01202.67
Kinnate Biopharma00403.00

Immunocore presently has a consensus price target of $54.3333, suggesting a potential upside of 53.18%. Kinnate Biopharma has a consensus price target of $52.00, suggesting a potential upside of 64.82%. Given Kinnate Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Kinnate Biopharma is more favorable than Immunocore.

Earnings & Valuation

This table compares Immunocore and Kinnate Biopharma's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunocoreN/AN/AN/AN/AN/A
Kinnate BiopharmaN/AN/AN/AN/AN/A

Summary

Kinnate Biopharma beats Immunocore on 3 of the 3 factors compared between the two stocks.


Kinnate Biopharma Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Abcam logo
ABCM
Abcam
1.5$19.89+1.0%$4.51 billionN/A0.00
SEER
Seer
1.2$51.99+3.2%$3.17 billionN/A0.00Gap Down
Nuvation Bio logo
NUVB
Nuvation Bio
1.9$10.00+0.2%$2.18 billionN/A0.00Analyst Report
IBRX
ImmunityBio
1.7$16.87+10.8%$1.84 billionN/A0.00Analyst Report
Analyst Revision
News Coverage
Gap Down
BioAtla logo
BCAB
BioAtla
1.5$47.35+0.7%$1.59 billionN/A0.00
Immunocore logo
IMCR
Immunocore
1.3$35.47+2.3%$1.53 billionN/A0.00Gap Down
Cullinan Oncology logo
CGEM
Cullinan Oncology
1.5$32.30+5.8%$1.41 billionN/A0.00News Coverage
Gap Down
EWTX
Cricut
0.3$29.54+1.6%$1.41 billionN/A0.00News Coverage
Silverback Therapeutics logo
SBTX
Silverback Therapeutics
1.7$38.07+5.4%$1.33 billionN/A0.00Analyst Report
Analyst Revision
News Coverage
Gap Down
Nurix Therapeutics logo
NRIX
Nurix Therapeutics
2.0$29.12+9.2%$1.29 billionN/A0.00Gap Down
Vor Biopharma logo
VOR
Vor Biopharma
1.9$32.02+5.2%$1.19 billionN/A0.00Gap Down
FDMT
4D Molecular Therapeutics
1.1$37.69+7.7%$951.07 millionN/A0.00
CNTB
Connect Biopharma Holdings Limited American Depositary Shares
0.0$17.00+3.5%$948.89 millionN/A0.00News Coverage
Gap Up
iTeos Therapeutics logo
ITOS
iTeos Therapeutics
1.9$27.01+11.1%$948.02 millionN/A0.00Analyst Report
Insider Selling
Analyst Revision
News Coverage
Gap Down
Pharvaris B.V. logo
PHVS
Pharvaris B.V.
1.4$28.32+0.1%$901.71 millionN/A0.00News Coverage
Gap Down
Gracell Biotechnologies logo
GRCL
Gracell Biotechnologies
1.5$13.50+6.1%$885.10 millionN/A0.00Analyst Downgrade
Gap Down
PHAR
Pharming Group
0.0$13.26+0.0%$845.93 millionN/A0.00
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.6$23.19+2.0%$842.45 millionN/A0.00Analyst Report
Analyst Revision
News Coverage
FNCH
Finch Therapeutics Group
0.3$17.18+1.9%$809.95 millionN/A0.00
Gemini Therapeutics logo
GMTX
Gemini Therapeutics
1.7$13.22+6.1%$568.45 millionN/A0.00Analyst Report
Analyst Revision
News Coverage
Gap Down
SGTX
Sigilon Therapeutics
1.4$17.76+1.7%$559.32 millionN/A0.00News Coverage
Inventiva logo
IVA
Inventiva
1.4$14.44+2.2%$557.76 millionN/A0.00Gap Down
Terns Pharmaceuticals logo
TERN
Terns Pharmaceuticals
2.0$18.93+2.9%$475.62 millionN/A0.00News Coverage
Gap Up
Angion Biomedica logo
ANGN
Angion Biomedica
1.7$15.48+1.4%$456.41 millionN/A0.00Gap Down
Sensei Biotherapeutics logo
SNSE
Sensei Biotherapeutics
2.0$14.13+4.7%$432.21 millionN/A0.00Gap Down
NexImmune logo
NEXI
NexImmune
2.0$17.85+2.4%$406.23 millionN/A0.00Gap Down
Landos Biopharma logo
LABP
Landos Biopharma
1.8$9.93+2.3%$398.37 millionN/A0.00Analyst Revision
PRTG
Portage Biotech
0.0$29.23+2.0%$353.19 millionN/A0.00News Coverage
Gap Down
Unity Biotechnology logo
UBX
Unity Biotechnology
1.1$5.83+1.0%$318.90 millionN/A-3.10
Kaleido Biosciences logo
KLDO
Kaleido Biosciences
1.8$7.07+6.2%$300.24 millionN/A-2.79Gap Down
LBPH
Longboard Pharmaceuticals
1.9$16.00+0.0%$270.67 millionN/A0.00Analyst Report
Analyst Revision
News Coverage
Decibel Therapeutics logo
DBTX
Decibel Therapeutics
2.2$10.54+0.8%$262.47 millionN/A0.00News Coverage
IPA
ImmunoPrecise Antibodies
0.0$12.28+5.1%$234.78 millionN/A0.00News Coverage
Annovis Bio logo
ANVS
Annovis Bio
0.0$26.54+0.1%$184.37 millionN/A0.00
GANX
Gain Therapeutics
0.0$13.98+0.1%$158.41 millionN/A0.00News Coverage
Gap Down
VINC
Vincerx Pharma
1.0$19.06+0.9%$156.39 millionN/A0.00Gap Down
LGVN
Longeveron
0.3$6.81+0.4%$127.40 millionN/A0.00
EVAX
Evaxion Biotech A/S
1.7$6.09+9.2%$116.92 millionN/A0.00High Trading Volume
Analyst Revision
News Coverage
Gap Up
UPC
Universe Pharmaceuticals
0.0$4.64+3.2%$100.92 millionN/A0.00
VRDN
Viridian Therapeutics
1.7$15.66+6.7%$61.20 millionN/A0.00Gap Down
Inhibikase Therapeutics logo
IKT
Inhibikase Therapeutics
0.0$5.62+0.4%$56.49 millionN/A0.00
VIRI
Virios Therapeutics
1.3$6.17+2.3%$51.40 millionN/A0.00Gap Down
NLS Pharmaceutics logo
NLSP
NLS Pharmaceutics
1.7$3.87+1.0%$45.59 millionN/A0.00Gap Down
VLON
Vallon Pharmaceuticals
0.3$4.66+1.3%$31.74 millionN/A0.00
VRPX
Virpax Pharmaceuticals
0.3$4.86+23.5%$24.03 millionN/A0.00News Coverage
CMMB
Chemomab Therapeutics
0.0$45.90+19.8%$21.30 millionN/A0.00High Trading Volume
News Coverage
Gap Down
VYNT
Vyant Bio
0.0$4.02+4.0%$16.42 millionN/A0.00Gap Down
BCTX
BriaCell Therapeutics
0.0$5.21+15.9%$4.02 millionN/A0.00High Trading Volume
Gap Up
ACHL
Achilles Therapeutics plc American Depositary Shares
0.0$13.78+5.3%$0.00N/A0.00Gap Down
ADiTx Therapeutics logo
ADTX
ADiTx Therapeutics
1.0$2.94+0.7%$0.00N/A0.00
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.